Skip to content
FY'25FY'24FY'23
Profitability
Gross margin80.2%-0.4pp80.6%-3.5pp84.1%+0.8pp
Operating margin21.1%+17.9pp3.2%+17.1pp-13.9%-5.4pp
Net margin16.9%+16.3pp0.6%+12.1pp-11.5%-6.9pp
EBITDA margin21.9%+17.4pp4.5%+17.1pp-12.5%-5.8pp
Free cash flow margin-7.5%-28.2%-27.2pp
Returns
Return on assets16.6%+16.2pp0.5%
Efficiency
Asset turnover+0.2×0.8×
Inventory turnover41×+37.6×3.4×+0.8×2.6×
Liquidity
Current ratio0.7×-0.2×0.9×-0.1×
Quick ratio0.7×-0.2×0.9×0.0×0.9×
Cash ratio0.2×-0.1×0.3×+0.1×0.2×
Leverage
Debt-to-assets0.3×0.0×0.3×+0.1×0.2×
Net debt / EBITDA0.6×-0.5×
Interest coverage5.8×+4.9×0.9×+5.2×-4.3×-1.5×
Per Share
Book value per share-$0.77+69.8%-$2.53-88.7%-$1.34-1,145%
Valuation
Market capitalization$4.49B+189%$1.55B-24.3%$2.05B
Enterprise value$4.64B+188%$1.61B-20.2%$2.02B
Price / earnings21.5×-200×221.9×
Price / sales3.6×+2.3×1.3×-0.6×1.9×
EV / EBITDA17.1×-12.7×29.8×
EV / sales3.7×+2.4×1.4×-0.5×1.8×
Free cash flow yield-2.1%-15%
Earnings yield4.7%+4.2pp0.5%+6.6pp-6.1%
PEG ratio

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Indivior Pharmaceuticals, Inc. 's profit margins?
Indivior Pharmaceuticals, Inc. (INDV) runs a 81.3% gross margin and a 25.8% operating margin, with a 19.4% net margin.
Where do Indivior Pharmaceuticals, Inc. 's ratios come from?
Every ratio is computed from Indivior Pharmaceuticals, Inc. 's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.